GRI Bio, Inc.

GRI Healthcare Biotechnology

In the quarter to June 2026, EPS grew 97.5% and free cash flow grew 54.3%, each against the same quarter a year earlier.

1.38 0.02 −1.43%
Market cap
$3.1M
P/E
0.0×
Fwd P/E
−4.2×
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
10.30 14.21 3.25 1.70
Net Debt/EBITDA
6.64 5.52 3.09 1.21
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.80) (2.97) (30.29) (24.71)
Book value per Share
5.70 8.50 61.18 21.29
Free Cash Flow
(1.45) (3.68) (2.97) (2.31)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates